Methenamine Hippurate Tablets Market Forecast 2024-2033: Growth Rate, Drivers, And Trends

The Methenamine Hippurate Tablets by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Methenamine Hippurate Tablets Market:

https://www.thebusinessresearchcompany.com/report/methenamine-hippurate-tablets-global-market-report

According to The Business Research Company’s Methenamine Hippurate Tablets, The methenamine hippurate tablets market size has grown strongly in recent years. It will grow from $8.97 billion in 2023 to $9.63 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to traditional uti treatment, antibiotic resistance concerns, clinical validation, physician prescription patterns, patient preference for non-antibiotic solutions.

The methenamine hippurate tablets market size is expected to see strong growth in the next few years. It will grow to $12.83 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to growing uti prevalence, rising antibiotic resistance concerns, advancements in uti management, healthcare focus on preventive therapies,clinical trials and research. Major trends in the forecast period include increased uti incidence, rising antibiotic resistance, preference for non-antibiotic treatments, focus on preventive healthcare, research and development.

An increasing geriatric population is expected to boost the growth of the methenamine hippurate tablets market going forward. Geriatric population refers to the population of older people of 60 years and above. Geriatric patients are more vulnerable to urinary tract infections due to a variety of factors such as decreased urine flow, an enlarged prostate, or kidney stones, thus methenamine hippurate tablets are required to treat these conditions. For instance, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations responsible for international public health, one in six individuals on the planet will be 60 or older by 2030. In 2021, there were 1.4 billion people over the age of 60. The number of persons who are 60 years or older globally will double by 2050 (2.1 billion). The number of people who are 80 years or older is projected to treble, reaching 426 million. Therefore, the increasing geriatric population is driving the growth of the methenamine hippurate tablets market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=9412&type=smp

The methenamine hippurate tablets market covered in this report is segmented –

1) By Type: 20 Tablets Or Bottle, 6 Tablets Or Bottle

2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

3) By Application: Uncomplicated UTIs, Healthcare-associated UTIs

4) By End User: Hospitals, Homecare, Specialty Clinics, Others End Users

Product innovations have emerged as the key trend gaining popularity in the methenamine hippurate tablets market. Major companies operating in the methenamine hippurate tablets market are developing innovative products to strengthen their position in the market. For instance, in August 2021, Custex, a US-based urinary health brand, launched Cystex Ultra Protection. The unique features of Cystex Ultra Protection include probiotics, cranberries, vitamin A, and bio-shield technology. The Cystex Ultra Protection is intended to treat recurrent UTIs and maintain urinary tract health in more than 90% of women.

The methenamine hippurate tablets market report table of contents includes: